Skip to main content
Erschienen in: Cancer Causes & Control 8/2007

01.10.2007 | Original Paper

Lack of evidence for effect modification by estrogen of association between body mass index and colorectal cancer risk among postmenopausal women

verfasst von: Yiting Wang, Eric J. Jacobs, Lauren R. Teras, Alexandre L. Pavluck, Carmen Rodriguez, Michael J. Thun, Eugenia E. Calle

Erschienen in: Cancer Causes & Control | Ausgabe 8/2007

Einloggen, um Zugang zu erhalten

Abstract

Objective

Previous studies of the association between body mass index (BMI) and colorectal cancer among women found increased risk only among women who were premenopausal or used hormone replacement therapy (HRT). These results led to the hypothesis that BMI may increase risk more strongly among women with higher levels of circulating estrogen. We examined the association between BMI and colorectal cancer incidence by use of HRT, and number of postmenopausal years without HRT, a measure of duration of exposure to lower levels of estrogen.

Methods

During follow-up from 1992–2003, 814 incident colorectal cancer cases were identified among 73,842 postmenopausal women in the Cancer Prevention Study-II Nutrition Cohort. Information on BMI and other risk factors was obtained from questionnaires completed at enrollment in 1992–1993 and during follow-up. Hazard ratios were calculated using proportional hazards modeling.

Results

The association between BMI and colorectal cancer incidence was similar among never–users of HRT (hazard ratio 1.13, 95% confidence interval 1.02–1.25 per 5-unit increase in BMI) and current-users of HRT (hazard ratio 1.08, 95% confidence interval 0.92–1.27 per 5-unit increase in BMI). Among women not currently using HRT, the association between BMI and colorectal cancer did not differ by postmenopausal years without HRT.

Conclusions

Our results do not support the hypothesis that BMI increases risk of colorectal cancer more strongly among women with higher levels of estrogen.
Literatur
1.
Zurück zum Zitat Gunter MJ, Leitzmann MF (2006) Obesity and colorectal cancer: epidemiology, mechanisms and candidate genes. J Nutr Biochem 17(3):145–156 MarPubMedCrossRef Gunter MJ, Leitzmann MF (2006) Obesity and colorectal cancer: epidemiology, mechanisms and candidate genes. J Nutr Biochem 17(3):145–156 MarPubMedCrossRef
2.
Zurück zum Zitat Frezza EE, Wachtel MS, Chiriva-Internati M (2006) Influence of obesity on the risk of developing colon cancer. Gut 55(2):285–291 FebPubMedCrossRef Frezza EE, Wachtel MS, Chiriva-Internati M (2006) Influence of obesity on the risk of developing colon cancer. Gut 55(2):285–291 FebPubMedCrossRef
3.
Zurück zum Zitat Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, Hubbell FA, Ascensao J, Rodabough RJ et al (2004) Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 350(10):991–1004 Mar 4PubMedCrossRef Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, Hubbell FA, Ascensao J, Rodabough RJ et al (2004) Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 350(10):991–1004 Mar 4PubMedCrossRef
4.
Zurück zum Zitat Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H et al (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. Jama 291(14):1701–1712 Apr 14PubMedCrossRef Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H et al (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. Jama 291(14):1701–1712 Apr 14PubMedCrossRef
5.
Zurück zum Zitat Newcomb PA, Storer BE (1995) Postmenopausal hormone use and risk of large-bowel cancer. J Natl Cancer Inst 87(14):1067–1071 Jul 19PubMedCrossRef Newcomb PA, Storer BE (1995) Postmenopausal hormone use and risk of large-bowel cancer. J Natl Cancer Inst 87(14):1067–1071 Jul 19PubMedCrossRef
6.
Zurück zum Zitat Grodstein F, Newcomb PA, Stampfer MJ (1999) Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 106(5):574–582 MayPubMedCrossRef Grodstein F, Newcomb PA, Stampfer MJ (1999) Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 106(5):574–582 MayPubMedCrossRef
7.
Zurück zum Zitat Terry PD, Miller AB, Rohan TE (2002) Obesity and colorectal cancer risk in women. Gut 51(2):191–194 AugPubMedCrossRef Terry PD, Miller AB, Rohan TE (2002) Obesity and colorectal cancer risk in women. Gut 51(2):191–194 AugPubMedCrossRef
9.
Zurück zum Zitat Wei EK, Ma J, Pollak MN, Rifai N, Fuchs CS, Hankinson SE et al (2005) A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 14(4):850–855 AprPubMedCrossRef Wei EK, Ma J, Pollak MN, Rifai N, Fuchs CS, Hankinson SE et al (2005) A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 14(4):850–855 AprPubMedCrossRef
10.
Zurück zum Zitat Schoen RE, Tangen CM, Kuller LH, Burke GL, Cushman M, Tracy RP et al (1999) Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst 91(13):1147–1154 Jul 7PubMedCrossRef Schoen RE, Tangen CM, Kuller LH, Burke GL, Cushman M, Tracy RP et al (1999) Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst 91(13):1147–1154 Jul 7PubMedCrossRef
11.
Zurück zum Zitat Castracane VD, Kraemer GR, Ogden BW, Kraemer RR (2006) Interrelationships of serum estradiol, estrone, and estrone sulfate, adiposity, biochemical bone markers, and leptin in post-menopausal women. Maturitas 53(2):217–225 Jan 20PubMedCrossRef Castracane VD, Kraemer GR, Ogden BW, Kraemer RR (2006) Interrelationships of serum estradiol, estrone, and estrone sulfate, adiposity, biochemical bone markers, and leptin in post-menopausal women. Maturitas 53(2):217–225 Jan 20PubMedCrossRef
12.
Zurück zum Zitat Yasui T, Uemura H, Umino Y, Takikawa M, Saito S, Kuwahara A et al (2005) Serum estrogen level after hormone replacement therapy and body mass index in postmenopausal and bilaterally ovariectomized women. Maturitas 50(1):19–29 Jan 10PubMedCrossRef Yasui T, Uemura H, Umino Y, Takikawa M, Saito S, Kuwahara A et al (2005) Serum estrogen level after hormone replacement therapy and body mass index in postmenopausal and bilaterally ovariectomized women. Maturitas 50(1):19–29 Jan 10PubMedCrossRef
13.
Zurück zum Zitat Lukanova A, Lundin E, Zeleniuch-Jacquotte A, Muti P, Mure A, Rinaldi S et al (2004) Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. Eur J Endocrinol 150(2):161–171 FebPubMedCrossRef Lukanova A, Lundin E, Zeleniuch-Jacquotte A, Muti P, Mure A, Rinaldi S et al (2004) Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. Eur J Endocrinol 150(2):161–171 FebPubMedCrossRef
14.
Zurück zum Zitat Lamon-Fava S, Barnett JB, Woods MN, McCormack C, McNamara JR, Schaefer EJ, et al (2005) Differences in serum sex hormone and plasma lipid levels in Caucasian and African-American premenopausal women. J Clin Endocrinol Metab 90(8):4516–4520 AugPubMedCrossRef Lamon-Fava S, Barnett JB, Woods MN, McCormack C, McNamara JR, Schaefer EJ, et al (2005) Differences in serum sex hormone and plasma lipid levels in Caucasian and African-American premenopausal women. J Clin Endocrinol Metab 90(8):4516–4520 AugPubMedCrossRef
15.
Zurück zum Zitat Slattery ML, Ballard-Barbash R, Edwards S, Caan BJ, Potter JD (2003) Body mass index and colon cancer: an evaluation of the modifying effects of estrogen (United States). Cancer Causes Control 14(1):75–84 FebPubMedCrossRef Slattery ML, Ballard-Barbash R, Edwards S, Caan BJ, Potter JD (2003) Body mass index and colon cancer: an evaluation of the modifying effects of estrogen (United States). Cancer Causes Control 14(1):75–84 FebPubMedCrossRef
16.
Zurück zum Zitat Hou L, Ji BT, Blair A, Dai Q, Gao YT, Potter JD et al (2006) Body mass index and colon cancer risk in Chinese people: menopause as an effect modifier. Eur J Cancer 42(1):84–90 JanPubMedCrossRef Hou L, Ji BT, Blair A, Dai Q, Gao YT, Potter JD et al (2006) Body mass index and colon cancer risk in Chinese people: menopause as an effect modifier. Eur J Cancer 42(1):84–90 JanPubMedCrossRef
17.
Zurück zum Zitat Lin J, Zhang SM, Cook NR, Rexrode KM, Lee IM, Buring JE (2004) Body mass index and risk of colorectal cancer in women (United States). Cancer Causes Control 15(6):581–589 AugPubMedCrossRef Lin J, Zhang SM, Cook NR, Rexrode KM, Lee IM, Buring JE (2004) Body mass index and risk of colorectal cancer in women (United States). Cancer Causes Control 15(6):581–589 AugPubMedCrossRef
18.
Zurück zum Zitat Pischon T, Lahmann PH, Boeing H, Friedenreich C, Norat T, Tjonneland A, et al (2006) Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst 98(13):920–931 Jul 5PubMedCrossRef Pischon T, Lahmann PH, Boeing H, Friedenreich C, Norat T, Tjonneland A, et al (2006) Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst 98(13):920–931 Jul 5PubMedCrossRef
19.
Zurück zum Zitat Terry P, Giovannucci E, Bergkvist L, Holmberg L, Wolk A (2001) Body weight and colorectal cancer risk in a cohort of Swedish women: relation varies by age and cancer site. Br J Cancer 85(3):346–349 Aug 3PubMedCrossRef Terry P, Giovannucci E, Bergkvist L, Holmberg L, Wolk A (2001) Body weight and colorectal cancer risk in a cohort of Swedish women: relation varies by age and cancer site. Br J Cancer 85(3):346–349 Aug 3PubMedCrossRef
20.
Zurück zum Zitat Polderman KH, Gooren LJ, Asscheman H, Bakker A, Heine RJ (1994) Induction of insulin resistance by androgens and estrogens. J Clin Endocrinol Metab 79(1):265–271 JulPubMedCrossRef Polderman KH, Gooren LJ, Asscheman H, Bakker A, Heine RJ (1994) Induction of insulin resistance by androgens and estrogens. J Clin Endocrinol Metab 79(1):265–271 JulPubMedCrossRef
21.
Zurück zum Zitat Tchernof A, Despres JP, Dupont A, Belanger A, Nadeau A, Prud’homme D et al (1995) Relation of steroid hormones to glucose tolerance and plasma insulin levels in men. Importance of visceral adipose tissue. Diabetes Care 18(3):292–299 MarPubMedCrossRef Tchernof A, Despres JP, Dupont A, Belanger A, Nadeau A, Prud’homme D et al (1995) Relation of steroid hormones to glucose tolerance and plasma insulin levels in men. Importance of visceral adipose tissue. Diabetes Care 18(3):292–299 MarPubMedCrossRef
22.
Zurück zum Zitat Calle EE, Rodriguez C, Jacobs EJ, Almon ML, Chao A, McCullough ML et al (2002) The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics. Cancer 94(9):2490–2501 May 1PubMedCrossRef Calle EE, Rodriguez C, Jacobs EJ, Almon ML, Chao A, McCullough ML et al (2002) The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics. Cancer 94(9):2490–2501 May 1PubMedCrossRef
23.
Zurück zum Zitat Stellman SD, Garfinkel L (1986) Smoking habits and tar levels in a new American Cancer Society prospective study of 1.2 million men and women. J Natl Cancer Inst 76(6):1057–1063 JunPubMed Stellman SD, Garfinkel L (1986) Smoking habits and tar levels in a new American Cancer Society prospective study of 1.2 million men and women. J Natl Cancer Inst 76(6):1057–1063 JunPubMed
24.
Zurück zum Zitat Allison P (1995) Survival analysis using the SAS system: a practical guide, SAS Press Allison P (1995) Survival analysis using the SAS system: a practical guide, SAS Press
25.
Zurück zum Zitat Moore LL, Bradlee ML, Singer MR, Splansky GL, Proctor MH, Ellison RC et al (2004) BMI and waist circumference as predictors of lifetime colon cancer risk in Framingham Study adults. Int J Obes Relat Metab Disord 28(4):559–567 AprPubMedCrossRef Moore LL, Bradlee ML, Singer MR, Splansky GL, Proctor MH, Ellison RC et al (2004) BMI and waist circumference as predictors of lifetime colon cancer risk in Framingham Study adults. Int J Obes Relat Metab Disord 28(4):559–567 AprPubMedCrossRef
26.
Zurück zum Zitat Movsesyan L, Tanko LB, Larsen PJ, Christiansen C, Svendsen OL (2003) Variations in percentage of body fat within different BMI groups in young, middle-aged and old women. Clin Physiol Funct Imaging 23(3):130–133 MayPubMedCrossRef Movsesyan L, Tanko LB, Larsen PJ, Christiansen C, Svendsen OL (2003) Variations in percentage of body fat within different BMI groups in young, middle-aged and old women. Clin Physiol Funct Imaging 23(3):130–133 MayPubMedCrossRef
27.
Zurück zum Zitat Gallagher D, Visser M, Sepulveda D, Pierson RN, Harris T, Heymsfield SB (1996) How useful is body mass index for comparison of body fatness across age, sex, and ethnic groups?. Am J Epidemiol 143(3):228–239 Feb 1PubMed Gallagher D, Visser M, Sepulveda D, Pierson RN, Harris T, Heymsfield SB (1996) How useful is body mass index for comparison of body fatness across age, sex, and ethnic groups?. Am J Epidemiol 143(3):228–239 Feb 1PubMed
28.
Zurück zum Zitat Murphy TK, Calle EE, Rodriguez C, Kahn HS, Thun MJ (2000) Body mass index and colon cancer mortality in a large prospective study. Am J Epidemiol 152(9):847–854 Nov 1PubMedCrossRef Murphy TK, Calle EE, Rodriguez C, Kahn HS, Thun MJ (2000) Body mass index and colon cancer mortality in a large prospective study. Am J Epidemiol 152(9):847–854 Nov 1PubMedCrossRef
29.
Zurück zum Zitat Van Pelt RE, Evans EM, Schechtman KB, Ehsani AA, Kohrt WM (2001) Waist circumference vs body mass index for prediction of disease risk in postmenopausal women. Int J Obes Relat Metab Disord 25(8):1183–1188 AugPubMedCrossRef Van Pelt RE, Evans EM, Schechtman KB, Ehsani AA, Kohrt WM (2001) Waist circumference vs body mass index for prediction of disease risk in postmenopausal women. Int J Obes Relat Metab Disord 25(8):1183–1188 AugPubMedCrossRef
30.
Zurück zum Zitat Giovannucci E (2001) Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 131(11 Suppl):3109S–3120S.NovPubMed Giovannucci E (2001) Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 131(11 Suppl):3109S–3120S.NovPubMed
Metadaten
Titel
Lack of evidence for effect modification by estrogen of association between body mass index and colorectal cancer risk among postmenopausal women
verfasst von
Yiting Wang
Eric J. Jacobs
Lauren R. Teras
Alexandre L. Pavluck
Carmen Rodriguez
Michael J. Thun
Eugenia E. Calle
Publikationsdatum
01.10.2007
Verlag
Kluwer Academic Publishers
Erschienen in
Cancer Causes & Control / Ausgabe 8/2007
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-007-9009-5

Weitere Artikel der Ausgabe 8/2007

Cancer Causes & Control 8/2007 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.